KOSDAQBiotech & Pharma217730

Kangstem Biotech

₩2,280▲ 0.22%2026-10-02 close

Market Cap

₩210.7B

Turnover

₩700M

Volume

290,000 shares

Shares out.

94.1M

PER

—

PBR

—

EPS

—

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

OSCA Trial Progress Amid Recurring Dilution

KangStem Biotech is progressing OSCA's Phase 2a knee osteoarthritis results and expanding its organoid business, while a shrinking revenue base and recurring capital-raising burden persist in parallel.

1
The July 2026 topline data for OSCA (knee osteoarthritis) showed statistical significance in both pain/function measures and MRI-based structural improvement indicators.
2
The atopic dermatitis candidate Furestem-AD failed to meet its primary endpoint in two domestic Phase 3 trials (2019, 2024), prompting a strategic pivot toward the Japanese regenerative medicine market and licensing.
3
Confirmed annual revenue fell for four straight years from KRW 16.3 billion in 2022 to KRW 3.57 billion in 2025, with operating losses persisting in the KRW 15–23 billion range each year.
4
Per a January 2026 disclosure, the pre-tax loss-to-equity ratio fell from 52% in 2023 to 14% in 2025, which the company said removed the risk of being designated an administrative issue.
5
In the organoid business, the company signed successive material-transfer and co-evaluation agreements with major pharmaceutical companies, including a global top-5 player, in July and August 2026, in an attempt to diversify new revenue sources.

Business structure

KangStem Biotech, founded in 2010 and listed on KOSDAQ in 2015, specializes in umbilical cord blood-derived stem cell therapeutics.

Based on its proprietary platform for high-purity isolation and mass culture of stem cells from cord blood, the company holds a pipeline including the atopic dermatitis candidate Furestem-AD, the knee osteoarthritis candidate OSCA (Furestem-OA Kit), the rheumatoid arthritis candidate Furestem-RA, and the Crohn's disease candidate Furestem-CD.

Based on proprietary multi-lineage stem cell technology involving high-purity isolation and mass culture from human umbilical cord blood, the company holds a stem cell therapeutic pipeline for atopic dermatitis, rheumatoid arthritis, and osteoarthritis.

Aside from OSCA, the rest of the pipeline remains in early clinical stages.

Beyond cell therapeutics, the company has also operated a cosmetics business based on stem cell culture media and, through its consolidated subsidiary Kroen, a non-clinical CRO business, and has more recently added a drug efficacy evaluation service business using skin and hair follicle organoids.

However, KangStem sold roughly 45 percentage points of its 64.5% stake in Kroen to HLB Biostep, reducing its holding to 29.67% and transferring management control.

In terms of commercial partnerships, the company signed a licensing and joint R&D agreement with Daewoong Pharmaceutical in December 2014 for stem cell therapeutics, under which Daewoong holds rights to two Furestem products, and in 2024 licensed out the OSCA osteoarthritis candidate to Yuyu Pharma, a domestic musculoskeletal specialty company, receiving an upfront payment and milestones totaling at least KRW 14 billion.

Founder Kang Kyung-sun serves as Chief Scientific Officer and has personally led invention of the core source technology and R&D for the skin organoid platform.

Earnings trend

Quarterly revenue · Operating profit

₩1B-₩4.4B25Q2₩500M-₩4.2B25Q325Q4₩800M-₩4.6B26Q1₩600M-₩6.1B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩16.3B-₩20.6B2022₩12.7B-₩22.8B2023₩7.7B-₩14.8B2024₩3.6B-₩17.7B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1B	-₩4.4B	−430.4%
2025Q3	₩500M	-₩4.2B	−864.6%
2025Q4	—	—	—
2026Q1	₩800M	-₩4.6B	−567.6%
2026Q2	₩600M	-₩6.1B	−944.3%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩16.3B	-₩20.6B	-₩20.2B	−126.1%	−41.0%	70.5%
2023	₩12.7B	-₩22.8B	-₩21.9B	−179.3%	−45.7%	82.5%
2024	₩7.7B	-₩14.8B	-₩8B	−191.6%	−18.5%	29.7%
2025	₩3.6B	-₩17.7B	-₩10.5B	−494.6%	−15.3%	18.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

On a confirmed financial basis, KangStem's revenue declined for four consecutive years, from KRW 16.3 billion in 2022 to KRW 12.7 billion in 2023, KRW 7.75 billion in 2024, and KRW 3.57 billion in 2025.

Operating losses persisted at over KRW 15 billion annually: KRW -20.56 billion in 2022, KRW -22.78 billion in 2023, KRW -14.84 billion in 2024, and KRW -17.67 billion in 2025.

Net loss attributable to owners widened to KRW -21.95 billion in 2023, then narrowed sharply to KRW -7.99 billion in 2024, a result driven by an equity valuation gain arising from the consolidation of affiliate Primoris Therapeutics, an exosome technology company, which sharply reduced net loss relative to the operating loss rather than any underlying profitability improvement.

Owner net loss widened again to KRW -10.48 billion in 2025.

Owner equity rose sharply from KRW 43.18 billion at end-2024 to KRW 68.65 billion at end-2025, likely reflecting the effect of a 2025 rights offering that raised roughly KRW 49 billion through a shareholder-allotment method with public offering of forfeited shares.

On a quarterly basis, operating losses were KRW -4.44 billion in Q2 2025 and KRW -4.19 billion in Q3 2025, before widening again to KRW -4.57 billion in Q1 2026 and KRW -6.06 billion in Q2 2026. Owner net losses also widened over the same period, to KRW -4.56 billion in Q1 2026 and KRW -6.25 billion in Q2 2026.

Quarterly revenue fluctuated in the KRW 0.6–1.0 billion range without a clear recovery signal.

The company did state, however, that its pre-tax loss-to-equity ratio fell from 52% in 2023 to 16% in 2024 and 14% in 2025, meaning the ratio did not exceed the threshold for two consecutive years and the related administrative-issue designation risk was fully resolved.

Industry analysis

The cell therapy industry remains an early-stage market with limited domestic commercialization success, with the regulatory bar high enough that no cell therapy approved in Korea has ever reached market authorization without meeting its primary efficacy endpoint.

Indeed, Furestem-AD completed a domestic Phase 3 trial in 2019 but failed as it did not meet the primary efficacy endpoint, and a second Phase 3 trial run under a revised protocol also failed to secure the primary efficacy endpoint.

This led the company to pivot from domestic approval toward the Japanese regenerative medicine market and global licensing, an area with high growth potential given that Japan's regenerative medicine market is projected to expand from JPY 290 billion this year to JPY 910 billion by 2040.

In osteoarthritis, industry observers note that rapid global aging has pushed the estimated patient population to around 600 million, while currently marketed treatments remain largely symptomatic rather than curative.

Because disease progression cannot be halted, unmet medical need is high among moderate-to-severe patients, a backdrop favorable to OSCA given its structural-improvement signal.

In the organoid field, adoption of New Approach Methodologies (NAMs) that replace animal testing has been expanding rapidly, particularly in the US and Europe, giving KangStem's skin and hair follicle organoid platform potential as a new revenue source in the drug efficacy evaluation market.

The organoid business, however, remains at an early contracting stage and its actual revenue contribution appears limited so far.

Outlook

The most visible near-term event is the Phase 2a topline data for the osteoarthritis candidate OSCA.

On July 28, 2026, the company disclosed topline results showing that at week 24, the treatment group showed statistically significant differences from placebo across pain measures including VAS, IKDC, WOMAC, and KOOS, and also showed statistical significance on the MRI-based MOCART index, confirming a structural improvement signal.

The company said it plans to present these results at the ACR Convergence in Florida in November 2026, with 12-month follow-up data to be disclosed at the EULAR and ISAKOS conferences in 2027.

For OSCA, the company set a goal of filing an IND application with the US FDA in December 2027 while also pursuing Regenerative Medicine Advanced Therapy (RMAT) and breakthrough therapy designations.

Domestic commercialization rights are already licensed to Yuyu Pharma, under a structure in which Yuyu will handle manufacturing and supply for domestic sales after approval, while KangStem collects sales royalties.

In the organoid business, the company signed a material transfer and evaluation agreement (MTEA) with a global top-5 pharmaceutical company for hair follicle organoid technology in July 2026, followed by an additional skin immune disease organoid co-evaluation research agreement with another top-tier global pharmaceutical company on August 31.

The company stated that meaningful organoid revenue began last year and it plans to disclose organoid revenue as a separate line item in this year's business report, meaning the scale of this new revenue source should become clearer going forward.

For the atopic dermatitis candidate, the company has set a goal of achieving annual revenue of over KRW 50 billion by 2029 through supply into Japan's regenerative medicine market rather than domestic approval, though recent updates on this progress have been limited.

Valuation

PER

—

PBR

—

ROE

-15.3%

EPS

—

BPS

—

Dividend per share

₩0

KangStem Biotech is a clinical-stage biotech without a stable revenue base, making traditional earnings-based valuation metrics difficult to apply.

Market capitalization trades at a premium relative to net asset value, which can be interpreted as reflecting market expectations for the future value of pipeline assets such as OSCA's clinical progress and the organoid business.

The company currently pays no dividend, so downside valuation support from dividend yield cannot be expected. The recurring rights offerings in 2018, 2021, 2023, and 2025 have repeatedly diluted share count, a persistent variable in per-share value calculations.

While recent positive events such as the OSCA trial results and organoid contracts continue, the timing at which this pipeline value converts into actual revenue and earnings remains uncertain.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

OSCA Phase 2a Efficacy Confirmed

The July 2026 OSCA Phase 2a topline data showed statistically significant improvement in pain and joint function measures versus placebo, along with a structural improvement signal on MRI-based evaluation.

The company stated it expects this to advance licensing discussions with multinational pharmaceutical and biotech companies. Domestic commercialization rights are already licensed to Yuyu Pharma, allowing royalty income after approval without the need to build a separate sales network.

Organoid Business Expansion

In July and August 2026, KangStem signed material-transfer and co-evaluation agreements with a global top-5 pharmaceutical company and an additional major global pharmaceutical company, respectively, both based on its organoid platform.

Combined with the regulatory tailwind of expanding NAMs adoption to replace animal testing, the skin and hair follicle organoid platform has potential to generate recurring evaluation-service revenue.

The company plans to disclose organoid revenue as a separate line item starting with its 2026 business report, which should improve revenue visibility.

Pre-Tax Loss Risk Resolved, Balance Sheet Stabilizing

The company disclosed in January 2026 that its pre-tax loss-to-equity ratio fell from 52% in 2023 to 14% in 2025, resolving the risk of administrative-issue designation. Equity expansion from the large 2025 rights offering also brought the debt ratio down. This supports the company's continued capacity to fund R&D.

Bear factors

Repeated Phase 3 Failures and Domestic Approval Uncertainty

Furestem-AD failed to meet its primary efficacy endpoint in two separate domestic Phase 3 trials, in 2019 and 2024. Industry observers have questioned the approval prospects, noting there is no precedent of a cell therapy receiving market approval in Korea without meeting its primary endpoint.

The company has pivoted toward the Japanese regenerative medicine market and licensing, but tangible revenue outcomes have not yet been confirmed.

Shrinking Revenue Base and Widening Losses

Annual revenue declined for four consecutive years, from KRW 16.3 billion in 2022 to KRW 3.57 billion in 2025, and the consolidated revenue base was further reduced by the 2025 divestment of the Kroen stake.

Quarterly operating losses, at KRW -4.4 billion and KRW -4.2 billion in Q2-Q3 2025, widened again to KRW -4.6 billion and KRW -6.1 billion in Q1-Q2 2026. Clear signs of revenue recovery or earnings improvement have yet to appear.

Recurring Capital Raises and Dilution Burden

KangStem has conducted rights offerings four times—in 2018, 2021, 2023, and 2025—resulting in repeated shareholder dilution. The 2025 offering, raising roughly KRW 49 billion, was implemented to cover cash flow disruption caused by the Phase 3 failure.

If licensing monetization from OSCA or the organoid business is delayed, the need for additional capital raises could resurface.

Risk factors

Clinical and Regulatory Risk

While OSCA achieved meaningful Phase 2a results, many steps remain—including further trials, a US IND, and RMAT designation—with no guaranteed outcome. As with Furestem-AD's two Phase 3 failures, the possibility that early positive signals fail to be replicated in subsequent trials cannot be ruled out.

Financial Risk

Fixed-cost burdens such as SG&A have persistently exceeded revenue by a wide margin, and expanding accumulated deficits continue to erode equity.

The pre-tax loss risk was recently resolved, but this was aided by one-off factors such as an affiliate equity valuation gain, meaning the issue could resurface if underlying business profitability does not improve.

Business Diversification Execution Risk

New businesses such as organoids and CDMO remain at an early contracting stage, and converting co-evaluation and material-transfer agreements into actual licensing or recurring revenue will take time.

Since the divestment of the Kroen stake reduced the existing CDMO/CRO revenue base, whether these new businesses can offset that loss remains a key question.

What to watch next

November 2026
OSCA's Phase 2a results are scheduled to be formally presented at the ACR Convergence in Florida; whether global partnership discussions advance following the presentation should be monitored.
Q3-Q4 2026
Upcoming quarterly disclosures should be checked for signs of revenue recovery and the extent to which the organoid and CDMO segments contribute to revenue.
First half of 2027
OSCA's 12-month follow-up data are expected to be disclosed at the EULAR and ISAKOS conferences, a point at which the durability of the early structural-improvement signal can be assessed.
December 2027
This is the company's targeted timing for filing OSCA's US FDA IND application; whether the plan proceeds as scheduled and the outcome of RMAT/breakthrough therapy designation efforts should be confirmed.

Overall view

Having experienced two domestic Phase 3 failures for its flagship atopic dermatitis candidate, KangStem Biotech is shifting its growth axis toward the osteoarthritis candidate OSCA and its organoid business.

On a confirmed financial basis, revenue declined for four consecutive years and operating losses persisted above KRW 15 billion annually, though the pre-tax loss risk that could have triggered administrative-issue designation was resolved as equity expanded via the large 2025 rights offering and an affiliate equity valuation gain.

The OSCA Phase 2a topline data disclosed in July 2026 confirmed both pain/function improvement and a structural improvement signal, which has been viewed as a positive input for subsequent trials and licensing discussions.

Over the same period, the organoid business also attempted to diversify new revenue streams by signing successive agreements with major pharmaceutical companies, including a global top-5 player.

However, quarterly operating and net losses widened again in the first half of 2026, and the history of shareholder dilution from repeated rights offerings should also be weighed.

This is a period where positive clinical and licensing momentum coexists with an as-yet unclear revenue recovery and ongoing financial burden, making it important to track upcoming quarterly results alongside the progress of clinical and contractual follow-through.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.